Halozyme Therapeutics (HALO) Earnings Date, Estimates & Call Transcripts $64.20 +0.17 (+0.26%) As of 02:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Halozyme Therapeutics Earnings Summary Halozyme Therapeutics announced Q2 2025 earnings on August 5, 2025, reporting an EPS of $1.54, which beat the consensus estimate of $1.23 by $0.31. Quarterly revenue rose 40.8% year-over-year to $325.72 million, above analysts' expectations of $282.66 million. With a trailing EPS of $4.37 and a P/E Ratio of 14.70, Halozyme Therapeutics' earnings are expected to grow 31.50% next year, from $4.73 to $6.22 per share. Upcoming Q3 Earnings DateOct. 30After Market ClosesEstimatedConsensus EPS (Aug. 5) $1.23 Actual EPS (Aug. 5) $1.54 Beat By $0.31 Actual Revenue (Aug. 5) $325.72MQ2 2025 Earnings ResourcesQ2 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q) Slide DeckHALO Upcoming EarningsHalozyme Therapeutics' next earnings date is estimated for Thursday, October 30, 2025, based on past reporting schedules. Slide DeckFull Screen Slide DeckPowered by Get Halozyme Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Halozyme Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataHALO Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.HALO Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Halozyme Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateRevenue EstimateCompany EPS GuidanceCompany Revenue GuidanceQ1 20252$0.88$0.93$0.91Q2 20252$1.04$1.09$1.07Q3 20252$1.31$1.41$1.36Q4 20252$1.58$1.66$1.62 FY 2025 8 $4.81 $5.09 $4.95 Q1 20261$1.02$1.02$1.02Q2 20261$1.21$1.21$1.21Q3 20261$1.46$1.46$1.46Q4 20261$1.68$1.68$1.68 FY 2026 4 $5.37 $5.37 $5.37 Q1 20271$1.19$1.19$1.19 Halozyme Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 10/30/2025(Estimated)--------8/5/2025Q2 2025$1.23$1.54+$0.31$1.33$282.66M$325.72M5/6/2025Q1 2025$0.98$1.11+$0.13$0.93$231.21M$264.86M2/18/2025Q4 2024$1.17$1.19+$0.02$1.06$285.74M$298.01M8/6/2024Q2 2024$0.73$0.91+$0.18$0.98$204.94M$231.40M5/7/2024Q1 2024$0.64$0.71+$0.07$0.82$201.72M$195.88M2/20/2024Q4 2023$0.77$0.75 -$0.02$0.85$235.25M$230.04M11/6/2023Q3 2023$0.67$0.69+$0.02$0.77$219.47M$216.03M Halozyme Therapeutics Earnings - Frequently Asked Questions When is Halozyme Therapeutics' earnings date? Halozyme Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, October 30th, 2025 based off last year's report dates. Learn more on HALO's earnings history. What guidance has Halozyme Therapeutics issued on next quarter's earnings? Halozyme Therapeutics issued an update on its FY 2025 earnings guidance on Tuesday, August, 5th. The company provided earnings per share guidance of 6.000-6.400 for the period, compared to the consensus estimate of 5.500. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.3 billion. Did Halozyme Therapeutics beat their earnings estimates last quarter? In the previous quarter, Halozyme Therapeutics (NASDAQ:HALO) reported $1.54 earnings per share (EPS) to beat the analysts' consensus estimate of $1.23 by $0.31. Learn more on analysts' earnings estimate vs. HALO's actual earnings. How can I listen to Halozyme Therapeutics' earnings conference call? The conference call for Halozyme Therapeutics' latest earnings report can be listened to online. Listen to Conference Call How can I read Halozyme Therapeutics' conference call transcript? The conference call transcript for Halozyme Therapeutics' latest earnings report can be read online. Read Transcript How much revenue does Halozyme Therapeutics generate each year? Halozyme Therapeutics (NASDAQ:HALO) has a recorded annual revenue of $1.02 billion. How much profit does Halozyme Therapeutics generate each year? Halozyme Therapeutics (NASDAQ:HALO) has a recorded net income of $444.09 million. HALO has generated $4.37 earnings per share over the last four quarters. What is Halozyme Therapeutics' price-to-earnings ratio? Halozyme Therapeutics (NASDAQ:HALO) has a trailing price-to-earnings ratio of 14.70 and a forward price-to-earnings ratio of 13.58. The price/earnings-to-growth ratio is 0.38. What is Halozyme Therapeutics' EPS forecast for next year? Halozyme Therapeutics' earnings are expected to grow from $4.73 per share to $6.22 per share in the next year, which is a 31.50% increase. More Earnings Resources from MarketBeat Related Companies BIIB Earnings Date INCY Earnings Date UTHR Earnings Date NBIX Earnings Date BMRN Earnings Date EXEL Earnings Date EXAS Earnings Date IONS Earnings Date MDGL Earnings Date RGEN Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles CrowdStrike Faces Valuation Test Before Key Earnings ReportPost-Earnings, How Does D-Wave Stack Up Against Quantum Rivals?Why SoundHound AI's Earnings Show the Stock Can Move HigherAirbnb Beats Earnings, But the Growth Story Is Losing AltitudeDutch Bros Just Flipped the Script With a Massive Earnings BeatIs Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?Constellation Energy’s Earnings Beat Signals a New Era This page (NASDAQ:HALO) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access